Toll free

18002022232

Consultant, Hematology, Bone Marrow Transplant & Cellular Therapy

Dr. Naveen Vairamoorthy

Dr. Naveen Vairamoorthy is a Consultant, Hematology, Bone Marrow Transplant & Cellular Therapy with integrated expertise across laboratory and clinical hematology, currently practicing at a cellular therapy centre with hands-on experience in CAR T delivery pathways and complex hemato-oncology care.

With a strong track record in quality assurance, service redesign, and research-to-practice implementation, Dr. Vairamoorthy combines evidence-based medicine with compassionate, patient-centred care.

Beyond clinical excellence, he brings advanced analytical and IT skills (LaTeX, R, SPSS, Linux/shell scripting) to drive data-informed decisions, streamline workflows, and support digital education. An active member of the British Society for Hematology (BSH) and the European Hematology Association (EHA), Dr. Vairamoorthy remains at the forefront of contemporary hematology practice.

  • MBBS: Government Thanjavur Medical College, Thanjavur, Tamil Nadu, 2012
  • MD (Pathology): Seth GS Medical College & KEM Hospital, Mumbai, 2017
  • DipRCPath (Hematology): Royal College of Pathologists, London, UK, 2021
  • DrNB (Clinical Hematology): Sir Ganga Ram Hospital, New Delhi, 2025
  • Member: British Society for Hematology, since 2021
  • Member: European Hematology Association, since 2025

Current Roles & Expertise

Dr.  Naveen Vairamoorthy practices at a cellular therapy centre, contributing across the CAR T pathway: patient selection, bridging therapy coordination, inpatient/outpatient management, toxicity recognition and management (CRS, ICANS), and survivorship follow-up. Parallel laboratory leadership includes ISO 15189-aligned quality management, SOP authorship/revision, and EQA performance oversight. Dr.  Naveen Vairamoorthy supervises junior trainees, leads MDT discussions, and supports protocol development in hemato-oncology.

Key Clinical & Procedural Experience

  • Part of 180+ hematopoietic stem cell transplantations
  • 250+ bone marrow/trephine biopsies independently performed (reported under supervision)
  • 150+ lumbar punctures including intrathecal chemotherapy
  • PICC line insertions and removal of tunneled catheters
  • Day-care chemotherapy, transfusion support, and complex inpatient hemato-oncology care
  • Flow cytometry interpretation, advanced morphology, and integration of molecular diagnostics


Teaching & Educational Leadership

  • Recognised undergraduate teacher (NMC faculty database)
  • Developed 12+ haematopathology modules with digital microscopy and simulation
  • Led OSCE delivery and examiner roles; transitioned teaching to virtual platforms during the pandemic
  • Consistently high learner feedback (≈4.7/5), mentoring junior doctors and technical staff


Areas of Special Interest

  • Cellular therapy: Pathways, toxicity management, survivorship
  • Diagnostic integration: Flow cytometry, NGS-informed reporting in MDS/MPN
  • Quality systems: ISO 15189 accreditation, EQA optimisation, audit-to-change cycles
  • Data & digital: R-based analysis, LaTeX scientific writing, Linux scripting for reproducible research
  • Teaching innovation: Digital curricula, simulation, learner-centred assessment
  • National level hematology quiz – third prize, 2024
  • Certificate of appreciation (COVID-19 Response), Government of India, 2021
  • Second best paper in hematology, MAPCON, 2016
  • Research and travel grant recognitions at regional and international meetings

Selected Publications:

  1. Vairamoorthy N, Kazi B, and Patil V, 2025. Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. New England Journal of Medicine. 393(6), pp.619-620.
  2. Vairamoorthy N, Mondal S, Bansal N, Mishra N, Kotwal J, Gupta N. A Second Course of Horse ATG in Patients with Relapsed Severe Aplastic Anaemia-A Case Series. Indian Journal of Hematology and Blood Transfusion. 2024 Dec 31:1-3.
  3. Mondal S, Vairamoorthy N, Prakhar P, Kalra M, Kotwal J. Flowcytometric Assessment of Activated Cytotoxic T-cells in Rapid Diagnosis of Hemophagocytic Lymphohistiocytosis in Pediatric Patients. Indian Journal of Pediatrics. 2024 Aug:91(8):860.
  4. Mondal S, Gupta D, Vairamoorthy N, Moule P, Kotwal J, Gupta N. Azacytidine and Venetoclax as a Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion. 2024 Jun;41(1):197-199.

 

Selected Presentations:

  1. Unveiling Toxicity Patterns of Cellular Therapies Across Malignancies: A Multi-Centre Indian Experience, ESMO Asia Congress, Singapore, 2025
  2. Procalcitonin and CRP as Predictors of Bacteraemia in Neutropenic Fever – Asia-Pacific BMT Conference, 2024
  3. Invasive Fungal Infections: Clinical Profile and Outcomes – Haematocon, 2024
  4. Front-line Azacitidine and Venetoclax combination in Acute Myeloid Leukaemia – Haematocon, 2024
  5. Relapsed Severe Aplastic Anaemia: Second Course Horse ATG – Haematocon, 2023

 

Selected Projects:

  1. Procalcitonin Versus CRP in Febrile Neutropenia: Demonstrated superior performance of procalcitonin for detecting MDR Gram-negative bacteraemia and informed a new departmental pathway.
  2. Activated Cytotoxic T-Cell Phenotyping in Adult HLH: Identified a practical, flow-based activation threshold warranting validation as a diagnostic adjunct.

 

Selected Quality Improvement & Change Projects:

  1. Reflex Testing Pathways in MPN/MDS: Designed criteria-led reflex algorithms for molecular testing to optimise resource use and shorten turnaround times.
  2. ISO 15189 Accreditation & SOP Governance: Led internal audits, CAPA cycles, and SOP lifecycle management supporting successful accreditation/reaccreditation.
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male